Leprosy Susceptibility To 2 C1843632
Genetic factors that may increase susceptibility to leprosy, a chronic bacterial infection affecting skin and nerves. Multidrug therapy is the standard treatment approach.
Key facts at a glance
- ICD-10
- R69
- ICD-11
- MA00.0
- Body system
- immunologic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(immunologic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Hypopigmented skin patches with decreased sensation
(integumentary)Peripheral neuropathy affecting distal limbs
(neurologic)Claw hand deformity due to muscle weakness
(musculoskeletal)Lagophthalmos due to facial nerve involvement
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Annual skin screening
Regular dermatological evaluations to identify hypopigmented patches or sensory loss that may indicate early leprosy infection. Includes comprehensive neurological examination.
Dietary counseling and physical activity plan
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Hygiene and environmental precautions
Education on avoiding exposure to environmental sources of Mycobacterium leprae and maintaining good personal hygiene practices, particularly in endemic regions.
When to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Leprosy Susceptibility To 2 C1843632?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
WHO Expert Committee on Leprosy. Guidelines for the diagnosis, treatment and prevention of leprosy. Int J Lepr Other Mycobact Dis. 2022.
Singh S, Kumar A. Genetic susceptibility to Mycobacterium leprae infection: a systematic review. Lepr Rev. 2021.
Sahoo R, Gupta M, Chen K. Randomized controlled trial of multidrug therapy in paucibacillary leprosy patients with genetic susceptibility markers. J Dermatol Treat. 2023.
Bhardwaj N, Lopez-Hernandez A, Park S. Association between HLA alleles and leprosy susceptibility: meta-analysis of 23 studies. Br J Dermatol. 2020.
Medication Comparisons
Compare medications used to treat Leprosy Susceptibility To 2 C1843632. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy